Media headlines about Bellicum Pharmaceuticals (NASDAQ:BLCM) have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Bellicum Pharmaceuticals earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.4671982620649 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:
Several equities analysts have issued reports on the stock. ValuEngine upgraded shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, September 18th. Jefferies Group restated a “buy” rating and issued a $16.00 price objective on shares of Bellicum Pharmaceuticals in a research note on Thursday, September 14th. BidaskClub upgraded shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday. Raymond James Financial restated a “buy” rating on shares of Bellicum Pharmaceuticals in a research note on Tuesday, December 12th. Finally, Zacks Investment Research upgraded shares of Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 24th. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. Bellicum Pharmaceuticals presently has an average rating of “Hold” and an average price target of $26.20.
Bellicum Pharmaceuticals (NASDAQ BLCM) opened at $9.43 on Monday. Bellicum Pharmaceuticals has a 12 month low of $7.41 and a 12 month high of $15.55. The stock has a market cap of $313.27, a price-to-earnings ratio of -3.15 and a beta of 1.18. The company has a quick ratio of 6.08, a current ratio of 6.08 and a debt-to-equity ratio of 0.23.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.03. The business had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.03 million. During the same quarter last year, the company posted ($0.66) EPS. Bellicum Pharmaceuticals’s quarterly revenue was up 18.2% on a year-over-year basis. equities research analysts forecast that Bellicum Pharmaceuticals will post -2.93 EPS for the current fiscal year.
In other news, CFO Alan A. Musso sold 17,117 shares of the stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $9.33, for a total transaction of $159,701.61. Following the completion of the sale, the chief financial officer now owns 31,585 shares in the company, valued at $294,688.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Alan A. Musso sold 6,206 shares of the stock in a transaction dated Monday, November 27th. The stock was sold at an average price of $9.89, for a total transaction of $61,377.34. The disclosure for this sale can be found here. 18.77% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This report was originally reported by Equities Focus and is owned by of Equities Focus. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.equitiesfocus.com/2018/01/08/bellicum-pharmaceuticals-blcm-earning-somewhat-favorable-press-coverage-analysis-shows.html.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.